Liminatus Pharma, Inc. (Nasdaq: LIMN) announced that its board of directors has approved a 1-for-50 reverse stock split of its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE